Robin Jones to Sulfonamides
This is a "connection" page, showing publications Robin Jones has written about Sulfonamides.
Connection Strength
0.623
-
Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 05 01; 8(5):740-747.
Score: 0.199
-
Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Expert Opin Investig Drugs. 2019 Jun; 28(6):505-511.
Score: 0.162
-
Pazopanib, a promising option for the treatment of aggressive fibromatosis. Anticancer Drugs. 2017 04; 28(4):421-426.
Score: 0.140
-
Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer. 2020 01 01; 126(1):98-104.
Score: 0.042
-
Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). Clin Cancer Res. 2019 09 01; 25(17):5295-5300.
Score: 0.041
-
Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. JAMA Oncol. 2018 09 01; 4(9):e180219.
Score: 0.039